Are there gender differences in anti-HIV drug efficacy?

August 9, 2012, Mary Ann Liebert, Inc
©2012 Mary Ann Liebert, Inc., publishers

Women comprise nearly half of the HIV-infected population worldwide, but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug Administration (FDA) has created a database from 40 clinical studies to assess gender differences in the efficacy of antiretroviral treatments. The results of this study are presented in an article in AIDS Patient Care and STDs.

Guoxing Soon and coauthors from the FDA and University of Texas Southwestern Medical Center, Dallas, TX, found that women represented only about 20% of the subjects in randomized clinical trials submitted to the FDA between 2000 and 2008. The article "Meta-Analysis of Gender Differences in Efficacy Outcomes for HIV-Positive Subjects in Randomized Controlled Clinical Trials of Antiretroviral Therapy (2000-2008)" compares the effectiveness of anti- regimens reported for women versus men overall and among various subgroups.

The authors found no statistically or clinical significant differences between women and men in outcomes with regard to viral load after 48 weeks. However, they did report significant favoring males based on subgroup analyses.

"This is a critical area of research in terms of developing new HIV therapies," says Editor-in-Chief Jeffrey Laurence, MD, Director of the Laboratory for Research at Weill Medical College of Cornell University, New York, NY. "Mounting evidence indicates that metabolism of certain drugs varies in men vs. women, and side effects that interfere with adherence to these medications may also be manifest differently."

Explore further: HIV raises anal cancer risk in women, study says

More information: http://www.liebertpub.com/apc

Related Stories

HIV raises anal cancer risk in women, study says

April 16, 2012
(HealthDay) -- Women with HIV are at increased risk for anal cancer, a new study finds.

Recommended for you

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

Researchers find clues to AIDS resistance in sooty mangabey genome

January 3, 2018
Peaceful co-existence, rather than war: that's how sooty mangabeys, a monkey species found in West Africa, handle infection by SIV, a relative of HIV, and avoid developing AIDS-like disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.